Therapy of Type 2 Diabetes in Patients with SARS-CoV-2 Infection |
| |
Authors: | Weronika Bielka Agnieszka Przezak Andrzej Pawlik |
| |
Affiliation: | Department of Physiology, Pomeranian Medical University in Szczecin, 70-111 Szczecin, Poland; (W.B.); (A.P.) |
| |
Abstract: | COVID-19 infection poses an important clinical therapeutic problem, especially in patients with coexistent diseases such as type 2 diabetes. Potential pathogenetic links between COVID-19 and diabetes include inflammation, effects on glucose homeostasis, haemoglobin deoxygenation, altered immune status and activation of the renin-angiotensin-aldosterone system (RAAS). Moreover, drugs often used in the clinical care of diabetes (dipeptidyl peptidase 4 inhibitors, glucagon-like peptide 1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, metformin and insulin) may influence the course of SARS-CoV-2 infection, so it is very important to verify their effectiveness and safety. This review summarises the new advances in diabetes therapy and COVID-19 and provides clinical recommendations that are essential for medical doctors and for patients suffering from type 2 diabetes. |
| |
Keywords: | COVID-19 diabetes therapy |
|
|